This webinar will focus on HER2DX and its role in translating tumour biology into clinical care for patients with HER2-positive breast cancer.
Faculty will discuss the biological foundations of the assay, its genomic components, and its clinical utility in risk stratification and treatment decision-making. The session will highlight how HER2DX can support more personalised therapeutic strategies within a multidisciplinary framework.

ACKNOWLEDGMENTS
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.